Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.54 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.48 |
| ▸ | CCNK | O75909 | 2/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 2/20 | 0.41 |
| ▸ | CIT | O14578 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28331274 | 0.89 | CCNK (0.54) | FGFR1FGFR4ROCK1ROCK2CCNK | |
| SCHEMBL878696 | 0.81 | FGFR4 (0.81) | FGFR1FGFR4ROCK2CSF1RBRD4 | |
| SCHEMBL12127494 | 0.77 | BRD4 (0.70) | FGFR1KDRROCK1ROCK2CCNK | |
| SCHEMBL5322848 | 0.75 | LMNA (0.52) | FGFR1FGFR4CSF1R | |
| SCHEMBL22664552 | 0.74 | BRD4 (0.43) | FGFR1FGFR4ROCK1ROCK2CCNK | |
| SCHEMBL14416607 | 0.73 | PRKCI (0.50) | FGFR1KDRROCK1CCNKCDK12 | |
| SCHEMBL239630 | 0.73 | NUDT1 (0.54) | FGFR1KDRROCK1CCNKCDK12 | |
| SCHEMBL1329521 | 0.72 | CCNK (0.44) | FGFR1KDRROCK1ROCK2CCNK | |
| SCHEMBL29540648 | 0.71 | CCNK (0.56) | ROCK1ROCK2CCNKCDK12BRD4 | |
| SCHEMBL99955 | 0.71 | CCNK (0.56) | ROCK1ROCK2CCNKCDK12BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1696920-B1 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8067434-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | disclosed |
| EP-1696920-A4 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON INC (US) | 2009-09-02 | — | — | EP | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1696920-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005062795-A2 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | RET, GFRA3, GFRA1 | FGFR1 7/4885FGFR4 21/4885KDR 43/4885 |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | RET, FGFR1, FGFR3 | FGFR1 2/4885FGFR4 5/4885KDR 24/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | FGFR1 10/4885FGFR4 31/4885KDR 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.